27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
BeiGene Ltd (NASDAQ:BGNE) says it is aware that Pharmacyclics LLC has filed a complaint alleging that BeiGene's blood cancer therapy Brukinsa (zanubrutinib) infringes a Pharmacyclics patent issued on June 13, 2023. Pharmacyclics is an AbbVie Inc (NYSE:ABBV) company.
As per a Bloomberg Law report, AbbVie filed a lawsuit against the China-based company alleging a patent violation related to Brukinsa.
"BeiGene's work is original, and we will vigorously defend against all allegations of patent infringement," the company said.
Imbruvica (ibrutinib) is a once-daily oral medication jointly developed and commercialized by Janssen Biotech Inc, a unit of Johnson & Johnson (NYSE:JNJ) and Pharmacyclics.
BeiGene said that most recently, the ALPINE study, a head-to-head comparison between Brukinsa and Imbruvica in R/R CLL/SLL, demonstrated Brukinsa's superior efficacy (PFS and ORR) and safety (atrial fibrillation) over Imbruvica.
The study also reported zero sudden cardiac death events for Brukinsa versus a 1.9% rate for Imbruvica.
Global sales of Brukinsa reached $211.4 million for Q1 2023, compared to $104.3 million a year ago.
Price Action: BGNE shares are down 0.37% at $207.36 on the last check Thursday.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!